GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Defence Therapeutics Inc (XCNQ:DTC) » Definitions » EBITDA Margin %

Defence Therapeutics (XCNQ:DTC) EBITDA Margin % : 0.00% (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Defence Therapeutics EBITDA Margin %?

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Defence Therapeutics's EBITDA for the three months ended in Dec. 2023 was C$-8.26 Mil. Defence Therapeutics's Revenue for the three months ended in Dec. 2023 was C$0.00 Mil. Therefore, Defence Therapeutics's EBITDA margin for the quarter that ended in Dec. 2023 was 0.00%.


Defence Therapeutics EBITDA Margin % Historical Data

The historical data trend for Defence Therapeutics's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Defence Therapeutics EBITDA Margin % Chart

Defence Therapeutics Annual Data
Trend Jun20 Jun21 Jun22
EBITDA Margin %
- - -

Defence Therapeutics Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Sep23 Dec23
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Defence Therapeutics's EBITDA Margin %

For the Biotechnology subindustry, Defence Therapeutics's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Defence Therapeutics's EBITDA Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Defence Therapeutics's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Defence Therapeutics's EBITDA Margin % falls into.



Defence Therapeutics EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Defence Therapeutics's EBITDA Margin % for the fiscal year that ended in Jun. 2022 is calculated as

EBITDA Margin %=EBITDA (A: Jun. 2022 )/Revenue (A: Jun. 2022 )
=-7.32/0
= %

Defence Therapeutics's EBITDA Margin % for the quarter that ended in Dec. 2023 is calculated as

EBITDA Margin %=EBITDA (Q: Dec. 2023 )/Revenue (Q: Dec. 2023 )
=-8.255/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Defence Therapeutics  (XCNQ:DTC) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.


Defence Therapeutics EBITDA Margin % Related Terms

Thank you for viewing the detailed overview of Defence Therapeutics's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Defence Therapeutics (XCNQ:DTC) Business Description

Traded in Other Exchanges
Address
200 Burrard Street, Suite 1680, Vancouver, BC, CAN, V6C3L6
Defence Therapeutics Inc is engaged in the development of a biological drug enhancer platform that improves the efficacy and safety of a multitude of biological/biosimilar-based pharmaceuticals used in the treatment of cancer and infectious diseases. The Company has one operating segment, being research and development.